Please cite this article as: Steffes VM, Murali MM, Park Y, Fletcher BJ, Ewert KK, Safinya CR, Distinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies, Biomaterials (2017Biomaterials ( ), doi: 10.1016Biomaterials ( / j.biomaterials.2017 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. for cancer chemotherapy, albeit with little improvement over the standard-of-care. Improving efficacy requires an understanding of intramembrane interactions between PTXL and lipids to enhance PTXL solubilization and suppress PTXL phase separation into crystals. We studied the solubility of PTXL in cationic liposomes (CLs) composed of positively charged 2,3-dioleyloxypropyltrimethylammonium chloride (DOTAP) and neutral 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) as a function of PTXL membrane content and its relation to efficacy. Time-dependent kinetic phase diagrams were generated from observations of PTXL crystal formation by differential-interference-contrast microscopy. Furthermore, a new synchrotron small-angle x-ray scattering in situ methodology applied to DOTAP/DOPC/PTXL membranes condensed with DNA enabled us to detect the incorporation and time-dependent depletion of PTXL from membranes by measurements of variations in the membrane interlayer and DNA interaxial spacings. Our results revealed three regimes with distinct time scales for PTXL membrane solubility: hours for > 3 mol% PTXL (low), days for ≈ 3 mol% PTXL (moderate), and ≥ 20 days for < 3 mol% PTXL (long-term). Cell viability experiments on human cancer cell lines using CL PTXL nanoparticles (NPs) in the distinct CL PTXL solubility regimes reveal an unexpected dependence of efficacy on PTXL content in NPs. Remarkably, formulations with lower PTXL content and thus higher stability show higher efficacy than those formulated at the membrane solubility limit of ≈ 3 mol% PTXL (which has been the focus of most previous physicochemical studies and clinical trials of PTXL-M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 2 loaded CLs). Furthermore, an additional high-efficacy regime is seen on occasion for liposome compositions with PTXL ≥ 9 mol% applied to cells at short time scales (hours) after formation. At longer time scales (days), CL PTXL NPs with ≥ 3 mol% PTXL lose efficacy while formulations with 1-2 mol% PTXL maintain high efficacy. Our findings underscore the importance of understanding the relationship of the kinetic phase behavior and physicochemical properties of CL PTXL NPs to efficacy.
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3 administration to treat AIDS-related Kaposi's sarcoma [20] . PTXL in the form of Abraxane appears to be effective to treat metastatic melanoma, whereas the Taxol formulation is not [21] . Thus, development of novel drug delivery agents for established drugs may open new treatment avenues against an expanded range of cancers.
Liposomal nanoparticles (NPs) are versatile drug delivery agents due to their ability to sequester multiple distinct therapeutic molecules, including long and short nucleic acids (electrostatically condensed with membranes) [22] , as well as hydrophilic and hydrophobic drugs in different forms (solubilized, crystallized, surface-conjugated) [23] . Because each therapeutic drug molecule possesses unique physical and chemical characteristics, its liposomal carrier must be tailored to these properties to achieve efficient delivery [24] .
Studies suggest that longer retention times of an anticancer drug within circulating liposomes leads to greater accumulation of the drug at tumor sites [25, 26] . Much of this work has been done using DOX and other drugs that can be loaded efficiently in the interior aqueous pocket of liposomes (e.g. Doxil and Myocet) [27] . To prolong retention of these drugs in liposomes, the current approach is to increase the rigidity of the membrane and thereby reduce its permeability to hydrophilic drugs, by employing lipids with high melting points (e.g. with saturated tails) and including cholesterol.
Hydrophobic drugs, on the other hand, are solubilized by and reside directly in the nonpolar (hydrocarbon chain) region of the membrane (Fig. 1b,c) . These drugs, which include PTXL, are quickly expelled from membranes consisting of saturated lipid tails or those that have a high concentration of cholesterol [28] [29] [30] [31] [32] [33] . This observation indicates that the maximum loading and residence time of hydrophobic drugs within liposomes are particularly sensitive to the liposome composition. A key concern is that hydrophobic drugs will leach out of liposomes quickly in vivo because they reside at the particle boundary rather than the interior, and will subsequently bind to plasma proteins with hydrophobic pockets acting as 'lipid sinks' [23, 26, 34] .
Various studies indicate that liposome-PTXL formulations exhibit lower toxicity compared to Taxol®, may increase the maximum tolerated drug dose, and may improve biodistribution [30, [35] [36] [37] [38] . One liposomal formulation of PTXL is approved in China (Lipusu®) [39, 40] , while others are in clinical M A N U S C R I P T
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trials. Composition information for the Lipusu formulation is not publically available. LEP-ETU is in
Phase II trials in the United States; it is an anionic lipid-based carrier composed of the neutral lipid DOPC (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine), cholesterol, and cardiolipin (90:5:5 mole ratio) with an additional 3 mol% PTXL [41] . EndoTAG-1 is in Phase III trials in Taiwan and has a cationic liposome structure consisting of the univalent cationic lipid 2,3-dioleyloxypropyltrimethylammonium chloride (DOTAP), DOPC, and PTXL (50:47:3 mole ratio) [28] . Other types of PTXL-containing liposomes (e.g. PEGylated, antibody-targeted) have shown some promising early results, but have not progressed to clinical trials [30, 35, [42] [43] [44] [45] .
Straubinger has reported that 3 mol% is the solubility limit for PTXL in liposomes, above which PTXL rapidly precipitates [46] . However, there are few studies that systematically evaluate this drug loading parameter as a function of lipid and membrane properties and none that demonstrate that liposomes at this limit are the most efficient at actual drug delivery. Studies from various groups have investigated the behavior of PTXL in different types of membranes-cationic, anionic, neutral, cholesterolcontaining, saturated, and PEGylated-but these studies are few in number and together form a very fragmented and sometimes contradictory picture [29] [30] [31] [32] 44, 47] . What is lacking is a comprehensive study of how the physicochemical properties of liposome-PTXL particles, including their timedependent phase behavior, correlate to PTXL membrane content for optimal drug delivery and efficacy (i.e. ability to induce cancer cell death).
Cationic liposomes (CLs) are of particular interest because the electrostatic attraction between positive particles and the negatively charged sulfated proteoglycans (components of the glycocalyx which covers cells) leads to cell binding. Studies suggest that positively charged particles may achieve some cancerspecific targeting because the tumor neovasculature is more negatively charged than other tissues in the body and will therefore accumulate cationic particles at a higher concentration [42, [48] [49] [50] . This assertion was the basis for choosing the lipid mixture of EndoTAG-1 as a starting point in our investigation of PTXL-lipid interactions.
In the work reported here, we generated kinetic phase diagrams characterizing the time-dependent phase separation and crystal formation of PTXL as a function of PTXL content in DOTAP/DOPC membranes.
The phase diagrams were generated from direct observations of PTXL crystallization using differential-M A N U S C R I P T
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5 interference-contrast (DIC) microscopy. To corroborate this data, we used high-resolution synchrotron small-angle x-ray scattering (SAXS), which unambiguously identified the PTXL crystals by their characteristic diffraction peaks. Furthermore, SAXS allowed us to perform in situ measurements of variations in the membrane interlayer and DNA interaxial spacings in multilamellar, onion-like complexes of cationic DOTAP/DOPC/PTXL membranes condensed with DNA, confirming both incorporation of PTXL and its depletion from the membranes upon crystallization.
The kinetic phase diagrams show a solubility threshold at 3 mol% PTXL content: below 3 mol%, PTXL exhibits long-term solubility (≥ 20 days) in unsonicated CLs, whereas above 3 mol%, the drug crystallizes within the first day following hydration. PTXL remained soluble in CLs on a time scale of days when incorporated at 3 mol%. The duration of PTXL solubility in CL PTXL NPs consisting of small (< 200 nm diameter) unilamellar liposomes (produced by sonication) is shorter than in unsonicated (uniand multi-lamellar) liposomes with a broad distribution of larger sizes (average diameter ≈ 800 nm) over the whole range of PTXL contents tested.
While previous studies seem to empirically choose one or two PTXL-liposome formulations based on physical characterization alone to push forward directly into animal testing, our study breaks from that approach and instead attempts to correlate the extent of biological response to the liposome properties.
Thus, we assessed efficacy in vitro for a series of CL PTXL NPs with varying PTXL content in the CL membranes (at fixed total PTXL concentration in solution) by measuring human cancer cell survival.
We observed new drug delivery behavior dependent both on the PTXL content (i.e., PTXL loading) and the timing of drug delivery after liposome hydration (at short (hours) vs. long (days) times). CL PTXL NPs that exhibit long-term solubility (PTXL content ≤ 2 mol%) show the highest efficacy (extent of cell death), whether delivered hours or days after liposome hydration. In the majority of experiments, CL PTXL NPs containing ≥ 9 mol% PTXL exhibited greater efficacy than NPs with 3-7 mol% PTXL when the particles were applied to cells within a few hours of hydration. This effect disappears over time, as PTXL phase-separates and crystalizes. Thus, whereas previous studies (including clinical trials) of CL-based carriers have exclusively focused on 3 mol% PTXL content (i.e. near the CL solubility limit) [35, 41, 51] , our study has revealed two distinctly new PTXL composition regimes, below and above 3 mol% PTXL content, where CL PTXL NPs exhibit improved efficacy. Furthermore, our results M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 while neutral DOPC was exchanged for PTXL as the amount of PTXL was varied. The organic solvent was evaporated by a stream of nitrogen for 10 min and dried further in a vacuum (rotary vane pump) for 16 h. The resulting lipid/PTXL films were hydrated with high-resistivity water (18.2 MΩ cm) to the aforementioned concentrations. Immediately thereafter, suspensions were agitated with a tip sonicator (Sonics and Materials Inc. Vibra Cell, set to 30 Watt output) for 7 min to form small unilamellar vesicles ("sonicated liposomes").
Dynamic Light Scattering
A Malvern Zetasizer Nano ZS was used to measure the average size of the liposomes. A total of 100 µL of a 5 mM stock suspension was diluted with 900 µL of DMEM to mimic the salt conditions of the liposomes in solution when they are added to cells. This solution was loaded into a DLS cuvette (Malvern DTS1070) and measured. The liposome diameter is reported as the average ± standard deviation of 3 measurements.
Polarized optical microscopy
Liposome samples at a concentration of 5 mM were loaded into flat microslides (VitroCom) via capillary action and sealed on both ends with 5-min epoxy glue. Samples were observed under crossed polarizers on a Nikon Optiphot microscope with a 5× objective.
DIC microscopy
Samples prepared at 5 mM concentration were mixed manually after hydration by agitating the vial to ensure homogenous mixing. The sample solutions were stored at 37 °C for the duration of the experiment. At predetermined times, 2 µL aliquots were withdrawn, placed on microscope slides, covered by a coverslip kept in place by vacuum grease, and imaged at 10 or 20× magnification on an inverted Diaphot 300 (Nikon) microscope. The samples were first imaged within minutes of adding water to the dried lipid films, then every 2 h until 12 h, every 12 h until 72 h, and daily thereafter until PTXL crystals were observed or the entire sample was used up. The kinetic phase diagrams report an average time of PTXL solubility based on 2-4 independently formed samples for each mol% PTXL.
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Fluorescence microscopy
Liposomes were prepared as described above at 5 mM total concentration, except for the incorporation of two fluorophores, one for lipid and one for PTXL. The liposome composition was DOTAP:DOPC:OregonGreen-PTXL:TexasRed-DHPE=90:10:5:7.1 (molar ratio). An aliquot of 2 µL of this solution was placed between glass coverslip and slide and sealed in with vacuum grease. The solution was imaged with a Nikon Diaphot 300 equipped with a Nikon 1.4 NA 60× Plan Apo DIC Objective and a PCO Sensicam QE CCD camera.
X-ray scattering
X-ray scattering experiments were performed at the Stanford Synchrotron Radiation Lightsource (Beamline 4-2) with an x-ray energy of 9 keV and a sample-detector distance of 1.2 m. Lipid/PTXL films were prepared as described for liposome preparation (30 mol% DOTAP, 70-x PTXL mol% DOPC).
After hydration (to 20 mM, i.e., 6 mM DOTAP), lipid suspensions were placed in a bath sonicator for 30 min and then stored at room temperature. To prepare samples for x-ray scattering, aliquots of the liposome suspensions were mixed in 1.5 mm quartz capillaries (Hilgenberg) with calf thymus DNA solution (5 mg/mL in water) at a lipid/DNA charge ratio of 1.5. Samples were centrifuged in a capillary rotor in a Universal 320R centrifuge (Hettich, Germany) at 14,000 g for 30 min and the condensed lipid-DNA phase pelleted to the bottom of the x-ray capillary along with any PTXL crystals already present. Condensation of liposomes into CL-DNA complexes is expected to introduce confinement of crystal growth, which would complicate crystal detection by scattering. Thus, CL-DNA complexes were prepared immediately prior to measurement for each time point for each liposome composition under investigation, with the expectation that complex formation and centrifugation would break up newly formed crystals and disperse them heterogeneously into the CL-DNA pellet.
Concentrated lipid solutions with high PTXL content without DNA also produced opaque white pellets when centrifuged. X-ray scattering confirmed that these contained phase-separated PTXL. These results, shown in Figure 4a , are for samples using GMO as the neutral lipid in place of DOPC. The lipid only sample was DOTAP:GMO (50:50 mole ratio), while the PTXL sample had the composition DOTAP:GMO:PTXL (50:44:6 mole ratio).
Cell viability assays
Cells were plated in 96-well plates at a density of 5,000 cells/well. Cells were incubated overnight to adhere to the plate. Liposome suspensions were diluted in DMEM to reach the desired concentration of PTXL. The cell culture medium was then manually removed from the wells with a pipette (rather than a vacuum aspirator; to ensure that cells were not removed unintentionally) and replaced with 100 µL of the liposome suspension. After incubation for 24 h, the liposome-containing medium was removed manually with a pipette and replaced with supplemented DMEM. After incubation for another 48 Various groups have reported 3 mol% PTXL as the solubility limit in liposomes [41, 46] . Beyond this limit, PTXL phase-separates and forms characteristic needle-shaped crystals. Figure 1h shows a low-M A N U S C R I P T
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magnification polarized optical micrograph displaying such crystals in an unsonicated CL PTXL sample 5 days after hydration. While previous studies have largely relied on multi-step HPLC experiments to monitor drug loading and retention over time [30, 31, 43] , we set out to establish a DIC microscopy-based experimental protocol that would allow us to determine the PTXL stability in novel lipid formulations with higher throughput.
Nucleation and crystal growth theory, along with our experimental observations, suggests that the ratelimiting step in PTXL crystallization is nucleation, with crystal growth occurring on a much faster time scale thereafter. The experimental evidence supporting this is that the size of the crystals we observe in DIC microscopy is about 20 µm or larger. The resolution limit of DIC microscopy is much smaller, but we do not see evidence of smaller PTXL crystals. This suggests that the crystals grow to their large size very rapidly or, in other words, that nucleation is the rate-limiting step. Thus, direct observation of PTXL crystals using DIC microscopy is an appropriate technique to assess CL PTXL stability on the relevant time scale of hours to days. The phase diagrams show that PTXL is relatively unstable within membranes when it is incorporated at > 3 mol% in DOTAP/DOPC liposomes, phase separating on a time scale of hours to one day. In contrast, samples incorporating PTXL at ˂ 3 mol% PTXL are stable for at least a week, with unsonicated samples not phase separating within the timeline of observation (with selected samples monitored over 30 days). At 3 mol% PTXL content, PTXL-loaded CLs display moderate stability, which is reduced if the sample was subjected to sonication. Indeed, as evident from a comparison of Independent of the lipid composition, the x-ray scattering from liposome solutions (which do not pellet from centrifugation due to the similar densities of liposome and water) is weak ( Figure 4a ). To overcome this problem and enable detailed structural analysis of PTXL-loaded membranes we concentrated CL PTXL NPs by complexing them with oppositely charged macromolecules, using anionic DNA as the condensing agent (compare the lack of features in the range of q = 0.05-0.25 of Figure 4a to the well-defined peaks in same range in Figure 4c ). The resulting CL PTXL -DNA complexes can be further compacted into a high-membrane-concentration pellet by centrifugation. We verified that CL PTXL -DNA complexes (using either plasmid DNA or short 5 base-pair double-stranded DNA) had human cancer cell death efficacy equivalent to that of CL PTXL NPs (Figure 4b ). We also found that a moderate change in membrane charge density (DOTAP content of 30 versus 50 mol%) had no statistically significant effect on efficacy.
In the absence of PTXL, SAXS has shown that CL-DNA complexes form the lamellar L α C phase for CLs composed of DOTAP and DOPC [56] [57] [58] [59] . The multilayered structure of the L α C phase, consisting
of onion-like NPs with diameter ≈300-400 nm, is also directly observed in cryoTEM [60, 61] . (Table S1 ). Figure 6a ). Figure 6d shows that the DNA interaxial spacing increases when the PTXL content in the membrane is increased, similar to the behavior seen in Figure   6b . In this case, the number of molecules in the membrane is constant (DOPC is replaced with PTXL to increase the PTXL content). However, replacing a DOPC molecule with a shorter but thicker PTXL molecule (see Figure 1b) leads to an increase in the average distance between lipids (increase in the lateral area per lipid) and a lower membrane charge density. This lowering of the membrane charge density with increasing PTXL content drives the increase in DNA spacing (i.e., lowering of the anionic charge density) as noted above.
This data shows that our new methodology, of using cationic membranes complexed with oppositely charged DNA to produce highly condensed aggregates suitable for in situ high-resolution synchrotron SAXS studies, has enabled us to accurately detect and measure small variations in the membrane interlayer spacing and the DNA interaxial spacing due to changes in the relatively small amount of PTXL (< 5 mol%) incorporated in the cationic membranes as a function of time. After probing the time M A N U S C R I P T
scale of PTXL solubility in membranes using optical microscopy and SAXS, we set out to correlate the observed differences between formulations incorporating varied amounts of PTXL to their drug delivery efficacy as measured by their toxicity to human cancer cell lines in vitro. Figure S3 ) with statistical significance, but not in every experiment (observed in three of five experiments). We attribute this to the fact that membranes which are supersaturated with PTXL exhibit significant variability as to when crystals form, because they are more sensitive to external perturbations that promote nucleation. If crystallization occurs early (within the 72 hours required for PTXL to produce its cytotoxic effect), lower efficacy would result.
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The more sensitive response of PC3 cells to PTXL concentration (as illustrated by the steeper slope of the cell survival curve, see Figure S1 ) means that small changes in the amount of soluble/bioavailable PTXL will lead to larger differences in cell survival for PC3 than M21. This may explain the more dramatic differences in cell survival for PC3 cells treated with different liposomal formulations compared to the more incremental differences observed for M21 cells (see Figure S3 ).
To control for lipid toxicity-especially for CL PTXL NPs at low PTXL content, where the most lipid was administered to the cells-we measured the viability of PC3 and M21 cells incubated with increasing concentrations of DOTAP/DOPC (50:50, mol:mol) small unilamellar CLs. As evident from the data shown in Figure 8 , no toxicity is observed even at 100 µM total lipid, the upper limit tested in this control experiment. This is consistent with literature values for various lipids, which showed toxicity arising in the 100-200 µM range for the most toxic lipids in the study [63] , while toxicity does not set in until 3000-4000 µM for the common neutral lipids mixed-chain phosphatidylcholine (egg lecithin) and dipalmitoylphosphatidylcholine (DPPC). The final total lipid concentration in our experiments probing CL PTXL NP toxicity never exceeded 6 µM lipid, and therefore the observed toxicity is due to the delivered PTXL.
To verify the unexpected toxicity trends as a function of PTXL content, we expanded on the limited snapshot of information afforded by the experiments reported in Figure 7 . Thus, we measured the IC-50
for cell toxicity of CL PTXL NPs at PTXL contents of 1, 3, and 9 mol% for PC3 and M21 cells (Figure 9 ).
In these experiments NPs were added to cells within 2-3 hours after hydration. For both cell lines, efficacy (diminishing of cell survival) is greatest when PTXL is incorporated at only 1 mol% (and thus more lipid is used as a carrier). The IC-50 for CL PTXL NPs with 1 mol% PTXL is more than a factor of 2 lower than that for carriers with 3 mol% PTXL, both for PC3 (Figure 9a ) and M21 (Figure 9b As time progresses and the PTXL phase-separates and crystallizes (becoming biologically inert), it renders the lipid carriers with ≥ 3 mol% PTXL less and less effective, as we see in Figure 10 . Based on the fact that immediately after hydration no PTXL crystals are observed, we assume that essentially all PTXL is initially associated with the CL membranes (with a small amount dissolved in water, as determined by PTXL's partition coefficient and water solubility). We thus believe that the PTXL crystals initially nucleate in the membrane but then exit (and in some cases protrude) from the membrane as the crystal grows and its size and shape can no longer be contained in the membrane. The M A N U S C R I P T
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20 membranes containing supersaturated PTXL will be the reservoir for PTXL crystal growth, replenishing the small amount of PTXL dissolved in the aqueous phase as it is consumed by the growth of the crystal.
The improved activity of carriers with well-solubilized PTXL (1 mol% PTXL) can be readily rationalized by the fact that the drug remains bioavailable for longer. The toxicity of PTXL requires about 72 hours to take full effect [4] , and the properties of these carriers ensure that the drug will not phase separate in this period. If PTXL crystalizes from its delivery vehicle during the 72-hour window,
we expect a reduction in the cytotoxicity because the concentration of bioavailable PTXL is effectively lowered. (Remember also that PTXL without a carrier is less effective (Fig. S2 ).) Interactions with cellular components such as membranes and cytoplasmic proteins (e.g. leading to loss of lipid from the CL carrier and thus creating a supersaturated state) may accelerate crystallization and in particular cause CL PTXL NPs at the PTXL membrane solubility limit to be less stable than they appear outside of cells, e.g. in the kinetic phase diagram experiment.
Another aspect to consider for a mechanistic explanation of our findings is that the amount of lipid used to deliver a given amount of PTXL increases as the mol% PTXL in a formulation decreases. Since the particle size is constant, this results in an increased number of particles. For example, a formulation at 0.5 mol% PTXL content will contain six times as much lipid, and thus six times as many particles, as a formulation containing 3 mol% PTXL. At the same time, each of these particles will contain six times less PTXL. Since PTXL has to reach the cytoplasm to display its cytotoxic activity, our efficacy data shows that increasing the number of particles in solution increases the amount of PTXL delivered to the cytoplasm either directly from the plasma membrane or via endocytic pathways. Future cell microscopy studies will be essential to further elucidate the relevant mechanisms. It is also interesting to speculate that the known interactions of microtubules with CLs could play a role in the transfer of PTXL to the tubulin within the cell [64] .
The increased efficacy that reemerges in some experiments at higher PTXL loading (~9 mol%) on short delivery time scales is highly unexpected. It may be that at this concentration, with PTXL supersaturated in the membrane, PTXL molecules are readily expelled from the lipid membranes soon after hydration.
This PTXL may diffuse directly into the cell membranes, which appear as a "lipid sink." As noted, the increased efficacy at high PTXL content was not observed in all experiments. We attribute this to the M A N U S C R I P T
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fact that membranes which are super-saturated with PTXL exhibit significant variability as to when crystals form, because they are highly sensitive to external perturbations that promote nucleation. Thus PTXL may have crystallized sooner in the experiments where efficacy of particles at 9 mol% PTXL was similar to that of particles containing 3 mol% PTXL.
Conclusions
DIC optical microscopy and high-resolution synchrotron SAXS have allowed us to map the kinetic phase behavior of DOTAP/DOPC-based CL carriers of PTXL and correlate distinct stability and efficacy regimes. To date, all efficacy studies of liposome-based PTXL carriers (including in animal models and cancer chemotherapy clinical trials) have incorporated PTXL in lipid NPs near the membrane solubility limit at 3 mol% [35, 36, 41, 62] . In strong contrast, the work reported here shows that CL PTXL NPs incorporating PTXL below 3 mol% have notably higher efficacy in prostate (PC3) and melanoma (M21) human cancer cells for NP delivery both on short and longer time scales (hours and days after liposome preparation). We also observed a secondary high efficacy regime on short delivery time scales for CL PTXL NPs with ≥ 9 mol% PTXL in some experiments. A further significant finding of our study is that the efficacy of CL PTXL NPs with higher PTXL content (≥ 3 mol%) is strongly dependent on the time between NP preparation and delivery. Our results underscore the importance of the integrated approach we present in the paper (connecting physical characterization of the particles to in vitro efficacy) and reveal that achieving long-term PTXL solubility (rather than maximum PTXL loading at ~3 mol%) is a key parameter in improving the efficacy of liposomal drug delivery in vitro.
Our experiments suggest that DOTAP/DOPC liposomes loaded with 3 mol% PTXL are still likely to phase separate on a time scale of days. This was observed in plain water, and is likely to be accelerated by perturbations in a biological environment (e.g. due to interactions with cellular components such as membranes and cytoplasmic proteins). To our knowledge, it has not yet been explored if liposomes encapsulating PTXL below its solubility limit can improve pharmacokinetics, pharmacodynamics, or biodistribution in vivo. Future studies will investigate how the findings we present here translate to in vivo efficacy and confirm them for other cell lines. It may be counterintuitive to use particles below their nominal drug-loading capacity, but our data suggests that this may facilitate actual drug targeting and enhance therapeutic outcomes for hydrophobic drugs by improving drug retention, as long as the M A N U S C R I P T
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threshold of lipid toxicity is not exceeded. As past examples demonstrate [20, 21] , changing the physicochemical properties of the drug delivery vehicle may significantly alter the activity of PTXL and improve its efficacy against cancers that are not currently amenable to treatment with PTXL in the Taxol or Abraxane formulations.
Finally, we presented a new methodology involving in situ synchrotron SAXS of PTXL-loaded cationic multilamellar membranes condensed by DNA, which has allowed us to directly confirm the presence of PTXL in membranes and to observe the incorporation and time-dependent depletion of PTXL from membranes upon PTXL crystal formation by measuring small variations in the membrane interlayer and DNA interaxial spacings. We expect this nondestructive approach to be generally applicable to other hydrophobic molecules. Besides allowing for precise measurements of the dimension of PTXLcontaining membranes under realistic, bulk-water conditions, complexes of such membranes with DNA (or siRNA) constitute a promising class of dual-cargo delivery vehicles which may be used to deliver nucleic acids to work synergistically with the delivered PTXL [33] . Table S1 . Peak positions for x-ray samples. The (005) peak was fit using a Lorentzian function in Igor Pro (WaveMetrics). This 5 th harmonic was used to calculate the positions of the (004) and (001) peaks as tabulated here, as well as the lamellar spacing d lamellar . The (002) peak is reported as the maximum intensity point of the scattering data (without a fit). The position of q DNA was determined by fitting the scattering data to the sum of two Lorentzian functions (for the (001) peak and the DNA-DNA correlation peak, see caption of Figure 5 ) and this value was used to calculate d DNA . P1, P2, and P3 from PTXL crystals appear consistently at the same q.
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